(1) CAR-T Designated Drug Access Benefit: After reviewing and meeting the requirements for the Car-T Therapy Designated Drug Access Benefit, the Benefit Holder who is 18 years of age or older may receive the Car-T Therapy Designated Drugs at a pharmacy designated by the Successful Bidder, subject to the Limited Drug List and Scope of Use. The entitlement holder is not required to pay for the cost of such Car-T therapy designated drugs;
(2) Direct payment of CAR-T drug fees: ordering of CAR-T drugs at a specialized pharmacy with CAR-T operating rights and providing direct payment of CAR-T drug fees, as well as assisting the customer in reporting the purchase of drug information to the treating hospital;
(3) assisting in the completion of the process for the qualification of a hospital with a CAR-T therapy-qualified hospitals, including but not limited to CAR-T therapy medical review, leukocyte single-collection, CAR-T cell preparation, examination and pretreatment chemotherapy, CAR-T cell infusion, and monitoring and evaluation services;
(4) Specialty drug search services: find new specialty drugs allowed to be marketed in China for the benefit of equity holders (approved by the State Drug Administration) and purchase channels for the drugs through those allowed to be marketed;
(5) Specialty drug search services: find new specialty drugs for the benefit of equity holders (approved by the State Drug Administration and approved by the State Drug Administration and approved by the State Drug Administration and approved by the State Drug Administration) and provide direct payment services for CAR-T drug expenses. (approved by the State Drug Administration), this service only provides drug finding service;
(5) Clinical Trial Application Service: the equity holder initiates an online application on the platform of the successful bidder, and after obtaining the written consent of the equity holder, the successful bidder may provide the equity holder with application services for the clinical trial of a new oncology drug, i.e., assisting in the provision of the equity holder with the new indications and therapeutic solutions of the new drug at the clinical trial stage;
(6) Clinical Trial Application Service: the successful bidder may provide the equity holder with clinical trial application services of new oncology drugs, that is, assist the equity holder in the provision of therapeutic regimen;
(6) This special drug service is subject to the printing of a physical card.